Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.59 |
| ▸ | CA2 | P00918 | 4/20 | 0.59 |
| ▸ | ACHE | P22303 | 4/20 | 0.59 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.56 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.56 |
| ▸ | FAAH | O00519 | 6/20 | 0.51 |
| ▸ | DRD2 | P14416 | 3/20 | 0.50 |
| ▸ | DRD3 | P35462 | 3/20 | 0.50 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8603697 | 1.00 | CA1 (0.59) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL8066286 | 1.00 | CA1 (0.59) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL545767 | 0.94 | MTNR1A (0.63) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL8606735 | 0.94 | MTNR1A (0.63) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL8074296 | 0.94 | MTNR1A (0.63) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL345640 | 0.88 | NPC1 (0.49) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL388601 | 0.88 | MTNR1A (0.54) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL7280750 | 0.87 | FAAH (0.48) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL970670 | 0.87 | CA1 (0.56) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL8603749 | 0.87 | CA1 (0.56) | CA1CA2ACHEMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2697207-B1 | 3-(2-ARYL-CYCLOALKENYLMETHYL)-OXAZOLIDIN-2-ONE DERIVATIVES AS CHOLESTEROL ESTER TRANSFER PROTEIN (CETP) INHIBITORS | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2016-12-14 | — | — | EP | disclosed |
| US-9504675-B2 | Alpha-ketoheterocycles and methods of making and using | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-11-29 | — | — | US | disclosed |
| US-9504675-B2 | Alpha-ketoheterocycles and methods of making and using | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-11-29 | — | — | US | disclosed |
| US-9371294-B2 | Cycloalkenyl aryl derivatives for CETP inhibitor | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2016-06-21 | — | — | US | disclosed |
| EP-2670245-B1 | ALPHA-KETOHETEROCYCLES AND METHODS OF MAKING AND USING | SCRIPPS RESEARCH INST (US) | 2015-09-09 | — | — | EP | disclosed |
| US-20150119376-A2 | CYCLOALKENYL ARYL DERIVATIVES FOR CETP INHIBITOR | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2015-04-30 | — | — | US | disclosed |
| US-20140243334-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| EP-2697207-A2 | CYCLOALKENYL ARYL DERIVATIVES FOR CETP INHIBITOR | Chong Kun Dang Pharmaceutical Corp. (KR) | 2014-02-19 | — | — | EP | disclosed |
| US-20140031335-A1 | CYCLOALKENYL ARYL DERIVATIVES FOR CETP INHIBITOR | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2014-01-30 | — | — | US | disclosed |
| WO-2012141487-A2 | CYCLOALKENYL ARYL DERIVATIVES FOR CETP INHIBITOR | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2012-10-18 | — | — | WO | disclosed |
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| EP-0683236-B1 | Enzymatic process for the preparation of optical active tetralin-derivatives | SANOFI SYNTHELABO (FR) | 2000-08-09 | — | — | EP | disclosed |
| US-5719308-A | Enzymatic process for the preparation of optically active tetralin derivatives | SANOFI (FR) | 1998-02-17 | — | — | US | disclosed |
| US-5573949-A | Enzymatic process for the preparation of optically active Tetrahydro-2-naphthoic acids | SANOFI (FR) | 1996-11-12 | — | — | US | disclosed |
| EP-0683236-A1 | Enzymatic process for the preparation of optical active tetralin-derivatives | SANOFI (FR) | 1995-11-22 | — | — | EP | disclosed |
| EP-0678579-A1 | Enzymatic process for the preparation of optical active tetralin-derivatives | MIDY S.p.A. (IT) | 1995-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC2 | CA1 400/4885CA2 413/4885ACHE 3602/4885 |
| US-20150119376-A2 | CYCLOALKENYL ARYL DERIVATIVES FOR CETP INHIBITOR | CETP, MTTP, LCAT | CA1 4543/4885CA2 3634/4885ACHE 1233/4885 |
| US-20140243334-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | HDAC6, H1-3, H1-5 | CA1 844/4885CA2 826/4885ACHE 1149/4885 |
| US-20140031335-A1 | CYCLOALKENYL ARYL DERIVATIVES FOR CETP INHIBITOR | CETP, MTTP, LCAT | CA1 4543/4885CA2 3634/4885ACHE 1233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.